A rapidly deployed ward-based screen and isolate initiative for Clostridium difficile carriers during an outbreak averted 5 of 10 expected hospital-acquired infections without identified harms. Each infection avoided required screening 197 and isolating 4.4 patients. Targeted C. difficile screening resulted in outbreak mitigation.
METHODS
We implemented a prospective ward-based quality improvement intervention between October 2016 and October 2017. The VA Boston Healthcare System includes a 160-bed acute care hospital in which 40 beds are prioritized for the surgical services. Any patient admitted to the surgical intensive care, surgical step-down unit, or acute care surgical floor was eligible to be included, regardless of admitting diagnosis or service. Patients were excluded if they had active diarrhea at admission or were transferred from other wards. There was no screening of patients admitted to the medical wards during this time. The VA Boston Healthcare System's antibiotic stewardship program (primarily prior authorizations) and cleaning protocols were unchanged during this period. This work was approved as a nonresearch quality improvement project by the institutional review board at the VA Boston Healthcare System.
On the intervention wards, screening for C. difficile was standardized as part of the nursing intake for each new admission. After verbal consent from the patient, a perirectal swab sample was obtained and tested for C. difficile by polymerase chain reaction for the toxin B gene using the GeneXpert system (Cepheid) [10] . Results were reported in the medical record as a screening test, which included an educational electronic note and flag if positive. Asymptomatic carriers were then placed on contact isolation, similar to standard precautions for symptomatic patients with CDI. If diarrhea developed in asymptomatic carriers, they underwent assessment for symptomatic CDI per usual clinical practice. Patients remained on precautions for the duration of the acute care admission but were not automatically placed back on precautions if readmitted.
Detailed clinical data were collected for each patient with a perirectal test performed during the initial 8 months of the intervention. Repeated admissions during this time period were excluded. Patients were followed for up to 90 days to determine whether symptomatic CDI developed, defined as ≥3 loose stools in a 24-hour period without another known cause [11] . An episode of HA-CDI was defined by the development of symptomatic CDI during hospitalization ≥2 calendar days (48 hours) after admission, excluding those with a previous positive results within the last 56 days, per Department of Veterans Affairs policy [12] .
Clinical variables and outcomes among asymptomatic C. difficile carriers were compared with those in noncarriers, using univariate and multivariate methods (see the Supplement). Using an autoregressive integrated moving average (ARIMA) model performed with the standard Box-Jenkins method, we forecasted expected rates of HA-CDI per 10 000 bed-days of care throughout the intervention (Supplement).
A total of 1250 patients underwent screening on the surgical wards between October 2016 and October 2017. Patientlevel data was abstracted for 773 unique patients, of whom 24 (3.1%) were asymptomatic C. difficile carriers. The patients were primarily male (95%), white (89%), and >65 years of age (Supplementary Table 1) .
The rates of HA-CDI (per 10 000 bed-days of care) on the surgical service were 10.9 in 2015, 10.2 in 2016, and 3.0 in 2017 (January through October). Without the information on asymptomatic carriage from the admission screening test, the rates of HA-CDI (per 10 000 bed-days of care) would have been calculated as 13.3 in 2016 and 4.2 in 2017, representing misclassifications of 25% and 29%, respectively.
The ARIMA model demonstrated a gradual decline in HA-CDI rates (Figure 1) . The difference between the expected and observed HA-CDI rates comp was 5.0 patients over a 10-month period, resulting in a number needed to screen of 197, and a number needed to isolate of 4.4.
Among the 773 patients with additional data available, nonwhite race, prior hospitalization with surgery, recent antibiotic use, and prior CDI were univariately associated with an asymptomatic C. difficile carrier state (Supplementary Table 1 ). Recent hospitalization without surgery, recent subacute or long-term care admission, proton pump inhibitor (PPI) use, and alcohol use disorder were not associated. In the multivariate analysis, the strongest independent predictors of the C. difficile carrier state included prior CDI (odds ratio, 8.9; 95% confidence interval, 2.5-31.7) and recent hospitalization with surgery (6.2; 1.7-22.3) (Supplementary Table 1) .
Symptomatic CDI within 90 days of admission occurred in 15 of 773 patients (1.9%): 7 (29%) of 24 asymptomatic C. difficile carriers compared with 8 (1%) of 749 with negative results at admission (P < .05). Risk factors significantly associated with development of symptomatic CDI in the univariate analysis included C. difficile carriage, surgical intervention during the index hospitalization, and history of prior CDI (Supplementary  Table 2 ). In the multivariate analysis controlling for antimicrobial use, C. difficile carriage was the only factor independently associated with the development of HA-CDI, with a >25-fold increased risk among patients who were carriers at admission (odds ratio, 26.1; 95% confidence interval, 7.4-92.1).
Treatment was initiated in 2 asymptomatic carriers but was discontinued quickly after education of the provider. The initiative had no impact on bed flow or other untoward effects.
DISCUSSION
This is the first initiative in the United States to address the potential role of screening and isolation of asymptomatic C. difficile carriers in an outbreak setting as an adjunct to standard infection prevention measures. We demonstrate a definitive decline in HA-CDI rates in the 10-month period after the implementation of this initiative. This decrease is not attributable only to reclassification of carriers, because the reduction in HA-CDI rates persisted even after correction for misclassified cases. The ARIMA model further demonstrates the reduction in actual CDI cases compared with what would be expected based on our 7 years of prior data.
Despite the low rate of positivity, nearly 30% of asymptomatic carriers progressed to infection; this rate is much greater than in prior studies, where disease developed in approximately 10%-15% of carriers [3, 6, 13] . C. difficile carriage admission status identified nearly half of the patients in whom CDI developed within 90 days. More established variables, such as prior Figure 1 . Observed versus forecasted hospital-acquired Clostridium difficile (HA-CDI) incidence rates (per 10 000 bed-days of care), with forecasts based on an autoregressive integrated moving average (ARIMA) model. Abbreviations: Jan, January; Sept, September.
antibiotic exposure, PPI use, or history of prior CDI, were not significantly associated with active CDI development, probably because they were overpowered by the carrier variable, suggesting that carrier status is an overwhelming factor in CDI development. It is unclear whether other interventions, in addition to isolation, could be useful in this population; this was not addressed in the current study.
In older studies, treatment of carriers failed to show benefit in eradicating disease or reducing rates of HA-CDI [14] . In fact, findings from these studies have suggested that carrier states may be protective, although stratification of toxigenic and nontoxigenic strains was not performed [15] .
Others have evaluated this strategy on a hospital-wide basis and found similar benefits, including similar numbers needed to screen and isolate [9] . However, our work highlights a targeted ward-based approach that can be rapidly deployed in an outbreak setting to reduce rates of HA-CDI, without the resource burden and complexities of a hospital-wide universal screening initiative. In this targeted approach, the cost of materials alone for the screen was roughly annualized at $50 000 ($30 per test), not including nursing or microbiology laboratory time; this is much less than the expected cost savings from averting 5 cases of CDI ($30 000 per case, or $150 000) [16] .
The concept of tiered activities for hospital infections is not new, as the Centers for Disease Control and Prevention currently provides supplemental prevention strategies for facilities with high rates of HA-CDI. Our work suggests that screening and isolating could be a third tier for facilities in an outbreak setting.
A limitation of this initiative was the use of perirectal rather than rectal swab samples to assess for colonization status. Perirectal swab samples are known to have 70%-99% sensitivity for the detection of C. difficile colonization compared with rectal swab samples [10] . This limitation would bias us toward the null hypothesis because carriers would go undetected and potentially continue contributing to transmission and also be counted as hospital-acquired cases if they became symptomatic.
In conclusion, hospital CDI rates decreased in concordance with this rapidly deployed ward-based screen and isolate initiative, and 5 cases of HA-CDI were prevented. In an outbreak setting, screening of C. difficile carriers at admission could be beneficial as an added step to a prevention bundle.
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